Patient Information About LASIK

LASIK is not for everyone. It involves risk and the results are not guaranteed. You may not be a good candidate due to your career, an unstable glasses prescription, a very high or low correction, or large pupils. You may still need reading glasses, results may not be lasting, and more than one treatment may be required due to under or over-correction.

Side effects may include but are not limited to dry eye syndrome, which can be severe; visual symptoms including halo effect, glare, double vision, and/or starbursts, which can be debilitating; and the loss of vision. Glasses and/or contact lenses may be needed after surgery. LASIK is contraindicated in patients with collagen vascular, autoimmune or immunodeficiency diseases, in pregnant or nursing women, in patients with signs of keratoconus or abnormal corneal topography, in patients who are taking one or both of the following medications: Isotretinoin (Accutane®); Amiodarone hydrochloride (Cordarone®) and Sumatriptan (Imitrex®). LASIK is not recommended in patients who have diabetes, a history of Herpes simples or Herpes zoster eye disease, significant dry eye that is unresponsive to treatment and severe allergies.

The safety and effectiveness of LASIK has not been established in patients with progressive myopia, ocular disease, previous ocular surgery or trauma, glaucoma or thin corneas. After LASIK, it may be more difficult to see under certain circumstances such as dim light, rain, snow, fog, or glare from bright lights at night. Device malfunctions or errors during surgery and complications after surgery, such as infection, LASIK flap displacement and inflammation may require another procedure, aggressive therapy and may lead to a loss of vision.

More information is available at

WaveLight® EX500 Laser and iFS® Advanced Femtosecond Laser Patient Information

Please review this information from the laser manufacturer so you can make an informed decision about having the LASIK procedure. Click here to view the patient information at Alcon and Johnson & Johnson Vision.